Award: Presidential Poster Award
Jesse L. Carlin, PhD, Verna R. Lieberman, Arya Dahal, Madison S. Keefe, Changfu Xiao, PhD, Gunther Birznieks, MS, Mihael H. Polymeropoulos, MD
Vanda Pharmaceuticals, Washington, DC
Introduction: A Phase II multicenter, randomized, double-blind, placebo-controlled trial with gastroparesis subjects demonstrating delayed gastric emptying and moderate to severe nausea were randomized to receive oral 85mg tradipitant bid or placebo (1:1) for four weeks. Of the 152 patients enrolled, 60% of patients had idiopathic and 40% had diabetic gastroparesis.
Methods: The primary outcome was change in average nausea score from baseline, measured using the 5-point Gastroparesis Core Symptom Daily Diary (GCSDD). Overall gastroparesis symptoms were evaluated using the Gastroparesis Cardinal Symptom Index (GCSI), and Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM).
Results: A statistically significant and clinically meaningful improvement in nausea and overall gastroparesis symptoms was observed in patients on tradipitant. Subjects receiving tradipitant had a significant decrease in their average nausea score compared to placebo with LS mean difference (95% CI) of -0.53 (-0.92, -0.13, p=0.0099) as well as a significant increase in nausea free days (28.8% increase on tradipitant compared to 15.0% increase on placebo, p=0.0160). A complete nausea response as defined by a nausea severity score ≤ 1 at week 4 was found to occur in 33% of patients on tradipitant compared to 12% of patients on placebo (p=0.0013).A clinically meaningful response in overall gastroparesis defined as a 1-point or more improvement on the GCSI total score was observed in 46.6% of patients on tradipitant compared to 23.5% of patients on placebo (p=0.0053).
Discussion: Tradipitant treatment resulted in statistically and clinically meaningful improvements in nausea and overall gastroparesis symptoms. Tradipitant was well tolerated with comparable rates of adverse events between tradipitant and placebo groups. These robust efficacy results suggest tradipitant has the potential to become a first line pharmacological treatment for gastroparesis.
Citation: Jesse L. Carlin, PhD, Verna R. Lieberman, Arya Dahal, Madison S. Keefe, Changfu Xiao, PhD, Gunther Birznieks, MS, Mihael H. Polymeropoulos, MD. P2659 - TRADIPITANT COMPLETE RESPONDER ANALYSIS IN GASTROPARESIS PATIENTS. Program No. P2659. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.